Alexander Spira, MD, PhD, FACP

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Alexander I. Spira, MD, PhD, FACP, discusses the adagrasib in patients with non–small cell lung cancer in the phase 2 KRYSTAL-1 trial.

Alexander I. Spira, MD, PhD, FACP, discusses the examination of RTX-240 in a phase 1 trial with solid tumors.

Alexander I. Spira, MD, PhD, FACP, discusses the role of frontline brigatinib in ALK-positive non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, discusses the challenges of developing targeted therapies for patients with NRG1 fusion–positive non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).